Summary
Eli Lilly and Company (LLY) filed an 8-K on March 17, 2003, to report on a significant financing event that occurred around March 12, 2003. The company entered into an underwriting agreement to issue and sell a substantial amount of senior notes, totaling $500 million. This issuance is divided into two tranches: $300 million of 2.90% Notes due in 2008 and $200 million of 4.50% Notes due in 2018. This move indicates that Eli Lilly is actively managing its capital structure, likely to fund ongoing operations, research and development, or potential acquisitions. The specific interest rates and maturity dates suggest a strategic approach to debt financing, potentially leveraging favorable market conditions at the time. Investors should monitor how these funds are deployed to assess their impact on the company's future growth and profitability.
Key Highlights
- 1Eli Lilly entered into an underwriting agreement on March 12, 2003.
- 2The company plans to issue and sell $500 million in aggregate principal amount of senior notes.
- 3The issuance includes $300 million of 2.90% Notes due 2008.
- 4The issuance also includes $200 million of 4.50% Notes due 2018.
- 5The filing includes the forms of the 2.90% Note Due 2008 and the 4.50% Note Due 2018 as exhibits.